

Ivana Mikolasevic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2239235/publications.pdf>

Version: 2024-02-01

47
papers

1,251
citations

516710

16
h-index

377865

34
g-index

49
all docs

49
docs citations

49
times ranked

2047
citing authors

#	ARTICLE	IF	CITATIONS
1	Transient elastography (FibroScan [®]) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?. <i>World Journal of Gastroenterology</i> , 2016, 22, 7236.	3.3	193
2	Vitamin D Deficiency: Consequence or Cause of Obesity?. <i>Medicina (Lithuania)</i> , 2019, 55, 541.	2.0	175
3	Nonalcoholic fatty liver disease - A multisystem disease?. <i>World Journal of Gastroenterology</i> , 2016, 22, 9488.	3.3	148
4	Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?. <i>World Journal of Gastroenterology</i> , 2018, 24, 1491-1506.	3.3	95
5	Liver Disease During Pregnancy: A Challenging Clinical Issue. <i>Medical Science Monitor</i> , 2018, 24, 4080-4090.	1.1	78
6	Chronic Kidney Disease and Nonalcoholic Fatty Liver Disease Proven by Transient Elastography. <i>Kidney and Blood Pressure Research</i> , 2013, 37, 305-310.	2.0	61
7	Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4835.	4.3	53
8	Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1347-1353.	2.3	43
9	Natural History of Nonalcoholic Fatty Liver Disease: Implications for Clinical Practice and an Individualized Approach. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-10.	1.9	40
10	Nonalcoholic fatty liver disease (NAFLD) – a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients. <i>Clinical Interventions in Aging</i> , 2014, 9, 1295.	2.9	27
11	Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 355-362.	1.9	25
12	Nonalcoholic Fatty Liver Disease (NAFLD) And Cardiovascular Risk In Renal Transplant Recipients. <i>Kidney and Blood Pressure Research</i> , 2014, 39, 308-314.	2.0	23
13	Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study. <i>European Journal of Internal Medicine</i> , 2020, 82, 68-75.	2.2	22
14	Nonalcoholic Fatty Liver Disease (NAFLD)â€”A New Cardiovascular Risk Factor in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2016, 36, 427-432.	2.3	20
15	Non-Alcoholic Fatty Liver Disease Proven by Transient Elastography in Hemodialysis Patients: Is It a New Risk Factor for Adverse Cardiovascular Events?. <i>Blood Purification</i> , 2014, 37, 259-265.	1.8	18
16	Vitamin D for treatment of nonâ€œalcoholic fatty liver disease detected by transient elastography: A randomized, doubleâ€œblind, placeboâ€œcontrolled trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2097-2106.	4.4	17
17	Metabolic syndrome and nonâ€œalcoholic fatty liver disease after liver or kidney transplantation. <i>Hepatology Research</i> , 2016, 46, 841-852.	3.4	16
18	Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease. <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 451-458.	1.9	14

#	ARTICLE	IF	CITATIONS
19	Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy. <i>International Journal of Clinical Practice</i> , 2021, 75, e13947.	1.7	14
20	Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 474-479.	1.9	13
21	Clinical profile, natural history, and predictors of mortality in patients with acute-on-chronic liver failure (ACLF). <i>Wiener Klinische Wochenschrift</i> , 2015, 127, 283-289.	1.9	13
22	Non-Alcoholic Fatty Liver Disease and COVID-19 – Two Pandemics Hitting at the Same Time. <i>Medicina (Lithuania)</i> , 2021, 57, 1057.	2.0	13
23	Prevention of Infectious Complications in Acute Pancreatitis. <i>Pancreas</i> , 2019, 48, 1056-1060.	1.1	11
24	Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-12.	1.9	11
25	Liver and Nonliver-Related Outcomes at 2 Years Are Not Influenced by the Results of the FIB-4 Test and Liver Elastography in a Real-Life Cohort of Patients with Type 2 Diabetes. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-9.	1.9	11
26	Fatty liver allografts are associated with primary graft non-function and high mortality after transplantation. <i>Liver International</i> , 2017, 37, 1113-1115.	3.9	10
27	Epidemiological and clinical features of primary biliary cholangitis in two Croatian regions: a retrospective study. <i>Croatian Medical Journal</i> , 2019, 60, 494-502.	0.7	9
28	Accuracy of Controlled Attenuation Parameter and Liver Stiffness Measurement in Patients with Non-alcoholic Fatty Liver Disease. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 428-437.	1.5	8
29	Pre-existing liver disease in pregnancy: Cirrhosis, autoimmune hepatitis and liver transplantation. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 44-45, 101668.	2.4	7
30	Noninvasive markers of liver steatosis and fibrosis after liver transplantation – Where do we stand?. <i>World Journal of Transplantation</i> , 2021, 11, 37-53.	1.6	7
31	Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma – where do we stand?. <i>Croatian Medical Journal</i> , 2018, 59, 97-99.	0.7	6
32	Relationship between coffee consumption, sleep duration and smoking status with elastographic parameters of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. <i>International Journal of Clinical Practice</i> , 2021, 75, e13770.	1.7	6
33	Prevalence, predictors and age-related sexual and erectile dysfunction in patients with inflammatory bowel disease: A tertiary centre experience. <i>International Journal of Clinical Practice</i> , 2021, 75, e14486.	1.7	6
34	Relationship between non-alcoholic fatty liver disease and MIA syndrome. <i>Hemodialysis International</i> , 2015, 19, 472-481.	0.9	5
35	Nonalcoholic fatty liver disease – a growing public health problem. <i>Croatian Medical Journal</i> , 2021, 62, 1-3.	0.7	5
36	Non-alcoholic fatty liver disease and transient elastography. <i>Exploration of Medicine</i> , 2020, 1, 205-217.	1.5	4

#	ARTICLE	IF	CITATIONS
37	Role of Endoscopic Ultrasound in Liver Disease: Where Do We Stand?. <i>Diagnostics</i> , 2021, 11, 2021.	2.6	4
38	Association between Gastroesophageal Reflux Disease and Elastographic Parameters of Liver Steatosis and Fibrosis: Controlled Attenuation Parameter and Liver Stiffness Measurements. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-8.	1.9	3
39	CTLA-4 +49 and TNF-alpha-308 gene polymorphisms in celiac patients with exocrine pancreatic insufficiency. <i>Collegium Antropologicum</i> , 2013, 37, 1191-4.	0.2	3
40	Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-12.	1.9	2
41	Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature. <i>Current Drug Metabolism</i> , 2021, 22, 89-98.	1.2	2
42	External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-8.	1.9	2
43	Endoscopic retrograde cholangiopancreatography-induced and non-endoscopic retrograde cholangiopancreatography-induced acute pancreatitis: Two distinct clinical and immunological entities?. <i>World Journal of Gastrointestinal Endoscopy</i> , 2018, 10, 259-266.	1.2	2
44	The Accuracy of Serum Biomarkers in the Diagnosis of Steatosis, Fibrosis, and Inflammation in Patients with Nonalcoholic Fatty Liver Disease in Comparison to a Liver Biopsy. <i>Medicina (Lithuania)</i> , 2022, 58, 252.	2.0	2
45	Fecal microbiota transplantation "where are we?". <i>Croatian Medical Journal</i> , 2021, 62, 52-58.	0.7	1
46	Editorial Comment to Noninvasive assessment of kidney allograft fibrosis with shear wave elastography: A radiological-pathological correlation analysis. <i>International Journal of Urology</i> , 2018, 25, 456-456.	1.0	0
47	Croatian guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease. <i>Acta Clinica Croatica</i> , 2021, 60, 36-52.	0.2	0